Overview

• Project concept: Discover specific and bispecific small molecules inhibiting the adenosinergic pathway for immuno-oncology therapies
• Strategy: Create patentable high quality assets
• Project status: Selection of CD73/A2AR bispecific and A2AR or CD73 specific small molecules
• Primary indication: Combination with immune checkpoint therapies for non responder patients
• Administration: Oral administration
• Biomarker: Patient stratification: CD73 positive tumour, Biomarker of activity: Adenosine pathways and CD73 expression

_{1 Evotec, Toulouse, France} 

_{2 Exscientia Ltd. Lab 12 Dundee Incubator, James Lindsay Place, Dundee, DD15JJ. United Kingdom}